02/10
Headlines

PTCT

Sizzling Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Frontier Communications Corporation (NASDAQ:FTR), The Michaels Companies, Inc. (NASDAQ:MIK), Southwest Gas Corporation (NYSE:SWX), China Unicom (NYSE:CHU)

Kevin Long03 mins

PTC Therapeutics (NASDAQ:PTCT) EVP Neil Gregory Almstead sold 26,096 shares of PTC Therapeutics stock on the open market in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $60.26, for a total value of $1,572,544.96. PTC Therapeutics, Inc. (NASDAQ:PTCT) belongs to Healthcare sector. Its weekly performance is…

Read More

Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Chris Lewis02 mins

Johnson & Johnson (NYSE:JNJ) announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently…

Read More

Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), Gilead Sciences, Inc. (NASDAQ:GILD), PTC Therapeutics, Inc. (NASDAQ:PTCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

Jayne Crisman02 mins

US drugmaker Pfizer Inc (NYSE:PFE) on Monday abandoned its pursuit to buy AstraZeneca PLC, saying it does not plan to make an offer for the British drugmaker following the rejection of its final proposal last week. Pfizer Inc. (NYSE:PFE) stock performance was -0.57% in last session and finished the day at $29.49. Traded volume was…

Read More

Notable Movers: ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), PTC Therapeutics, Inc. (NASDAQ:PTCT), Orexigen Therapeutics, Inc. (NASDAQ:OREX), CytRx Corporation (NASDAQ:CYTR), ZIOPHARM Oncology (NASDAQ:ZIOP)

Kristen Barton03 mins

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) presented results from a global, multi-center, open-label, comparator-controlled phase II study in patients undergoing total knee replacement surgery or total knee arthroplasty (TKA). Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi’s Lovenox (enoxaparin). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock performance was 11.26% in last session and finished the day at…

Read More

Biotech Losers: PTC Therapeutics (NASDAQ:PTCT), Prosensa Holding (NASDAQ:RNA), Concert Pharmaceuticals Inc (NASDAQ:CNCE), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Richard Atkins03 mins

One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the…

Read More
FB Nasdaq FB Facebook

Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

Colin Pettis02 mins

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation…

Read More